Skip to main content

Building the next generation of biotech ventures

Welcome to BaseLaunch

We partner with scientists and entrepreneurs to help launch and grow exceptional biotech ventures developing cutting-edge therapeutics. And we know how to do this – so far our portfolio has raised over $800M in financing with an average first VC round of over $28M per company.

Money dollar Icon png

Up to $500,000
in financing

Access to our partners,
global biopharma & investors

Company & team
build out

Access to labs &
related infrastructure
where needed

Partners

We are very pleased to continue our commitment to BaseLaunch. Basel has always been home to great ideas and innovation and today it is a leading life sciences hub within Switzerland and globally.

James SabryGlobal Head of Roche Pharma Partnering

We are delighted to join BaseLaunch as a partner in the next phase of its company building activities. The Pureos team worked closely with BaseLaunch during the Series A funding of Alentis Therapeutics and has been very impressed by the team and the quality of the selected programs.

Klaus Breiner, PhDManaging Partner at Pureos Bioventures

This partnership will help us identify and build relationships with potential external collaborators from throughout Europe…

Dr. Adrian ZuercherVice President, Research Europe and Head of Plasma Protein Research, CSL Behring

Incubators and accelerators are central to the global healthcare start-up ecosystem. We have been collaborating with BaseLaunch since launch in supporting the growth and development of early-stage biotech ventures and recognize the contribution the team has made towards achieving their goals...

Nerida ScottHead, Johnson & Johnson Innovation

With our involvement in the review process and funding decisions through our investment board seat, we aim to contribute to BaseLaunch‘s company creation track record and leverage AbbVie‘s expertise in translating innovative science into novel therapeutics.

Christian SchubertVice President and Head of AbbVie Ventures, Cambridge, MA

Latest news

Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2

Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2

Basel, Switzerland - September 24, 2025, Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its…
metaLead Therapeutics Appoints David Urech as Member of the Board of Directors

metaLead Therapeutics Appoints David Urech as Member of the Board of Directors

Basel, Switzerland – September 23, 2025 – metaLead Therapeutics AG (“metaLead”) announces the appointment of David Urech, PhD, Founder and former Chief Executive Officer of…
Gibela publishes groundbreaking research in Hepatology

Gibela publishes groundbreaking research in Hepatology

We are pleased to share that the research of Gibela Therapeutics, our portfolio company, was featured on the cover of the Hepatology journal. The company is…
Synendos Appoints Dr. George Garibaldi as Chief Medical Officer

Synendos Appoints Dr. George Garibaldi as Chief Medical Officer

Basel, Switzerland – Synendos Therapeutics, the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced the appointment of Dr. George Garibaldi as Chief Medical…
We welcome BioDuro as our new domain partner

We welcome BioDuro as our new domain partner

We’re excited to share our new partnership with BioDuro, a trusted CRDMO with a 29-year proven track record and strong reputation for delivering high-quality, end-to-end…
Hemastatx joins BaseLaunch portfolio

Hemastatx joins BaseLaunch portfolio

We’re excited to welcome Hemastatx to our portfolio. Hemastatx, a spin-off from KU Leuven, has emerged from stealth with funding from BaseLaunch, Gemma Frisius Fund and…

Application cycle is now open!

The next deadline is 7th of January 2026